Latest Conference Articles

February 9th 2020, 8:22pm

PER® Winter Lung Cancer Conference

The standard of care for patients with small cell lung cancer has been trapped in a period of stagnation for the past several decades.

February 9th 2020, 4:15am

PER® Winter Lung Cancer Conference

The potential therapeutic benefits of immune checkpoint inhibitors as monotherapy as well as in combination with chemotherapy for patients with non–small cell lung cancer depend greatly on the timing of treatment initiation. However, for patients with EGFR, ALK, and other actionable mutations, identifying the optimal combination is a hurdle.

February 9th 2020, 2:03am

SGO Winter Meeting

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

February 9th 2020, 2:01am

SGO Winter Meeting

Carrie L. Langstraat, MD, gynecologic oncologist, Mayo Clinic, discusses the role of sentinel lymph nodes in patients with endometrial cancers.

February 9th 2020, 1:20am

SGO Winter Meeting

Floor J. Backes, MD, discusses the latest advancements made in the treatment of patients with ovarian cancer and the ongoing research efforts that are being made with novel combinations.

February 8th 2020, 11:59pm

PER® Winter Lung Cancer Conference

Advancements in the prevention and treatment of patients with lung cancer have picked up momentum over the past decade and now is the time to build on that progress according to Suresh S. Ramalingam, MD, FASCO.

February 8th 2020, 10:18pm

SGO Winter Meeting

Tumors from a significant percentage of patients with endometrial cancer at NYU Langone Health’s Perlmutter Cancer Center were found to have BRCA1/2 somatic mutations.

February 8th 2020, 8:36pm

PER® Winter Lung Cancer Conference

Jamie E. Chaft, MD, discusses the rise of immunotherapy in lung cancer and research with this treatment modality that is on the horizon.

February 8th 2020, 8:34pm

PER® Winter Lung Cancer Conference

Rogerio C. Lilenbaum, MD, discusses using PD-L1 as a predictive biomarker for immunotherapy and the search for additional biomarkers in lung cancer.

February 8th 2020, 7:51pm

PER® Winter Lung Cancer Conference

Benjamin P. Levy, MD, discusses emerging oncogenic markers in lung cancer and what impact they are poised to make on the paradigm.

February 8th 2020, 3:34am

SGO Winter Meeting

In ovarian cancer, disease that returns within 6 months of treatment following platinum-based therapy is defined as platinum-sensitive.

February 8th 2020, 2:57am

SGO Winter Meeting

Researchers and practicing physicians have done as much as possible with chemotherapy as a systemic treatment for endometrial cancers, and other modalities—alone and in combination—are likely to become standard of care in the coming years, Shannon N. Westin, MD, MPH, said during a presentation at the 2020 SGO Winter Meeting.

February 7th 2020, 3:28am

SGO Winter Meeting

Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.

January 28th 2020, 2:57am

Gastrointestinal Cancers Symposium (ASCO GI)

Analysis of patient-reported outcomes from the phase III IMbrave 150 study showed meaningful benefits in quality of life, functioning, and key symptoms with atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma.

January 27th 2020, 10:59pm

Gastrointestinal Cancers Symposium (ASCO GI)

Encorafenib plus cetuximab with or without binimetinib demonstrated longer maintenance of quality of life on patient-reported assessments over current standard of care in the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.

January 27th 2020, 5:08am

Gastrointestinal Cancers Symposium (ASCO GI)

Augusto Villanueva, MD, an assistant professor of the Division of Liver Diseases at the Tisch Cancer Institute of Icahn School of Medicine at Mount Sinai, discusses mutations and gene signatures for patients with hepatocellular carcinoma, a topic he presented at the 2020 Gastrointestinal Cancers Symposium.

January 27th 2020, 5:01am

Gastrointestinal Cancers Symposium (ASCO GI)

Eileen M. O’Reilly, MD, discusses the randomized phase II trial of gemcitabine and cisplatin versus gemcitabine and cisplatin and veliparib in patients with pancreas adenocarcinoma harboring a known germline BRCA or PALB2 mutation, which was presented at the 2020 Gastrointestinal Cancers Symposium.

January 27th 2020, 12:47am

Gastrointestinal Cancers Symposium (ASCO GI)

Third-line treatment of patients with metastatic colorectal cancer using regorafenib plus oral fluoropyrimidine TAS-102 provides clinically meaningful disease control with toxicities consistent with the safety profiles of either agent, according to data from the phase I dose-escalation trial REMETY presented at the 2020 Gastrointestinal Cancers Symposium.

January 27th 2020, 12:08am

Gastrointestinal Cancers Symposium (ASCO GI)

Ramucirumab as second-line therapy after sorafenib induces improved overall survival compared with placebo, irrespective of Barcelona Clinic Liver Cancer stage, in patients with intermediate-stage hepatocellular carcinoma and an elevated baseline level of alpha fetoprotein.

January 26th 2020, 9:22pm

Gastrointestinal Cancers Symposium (ASCO GI)

Tanios S. Bekaii-Saab, MD, examines the effectiveness of umbrella trials and their importance in aiding precision medicine in gastrointestinal oncology.